Trial · NCT03426345
Results by group104
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 104
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) | Placebo | Baseline | 23.4 | Standard Deviation 5.40 | score on a scale |
| Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) | Relamorelin 10 μg | Baseline | 24.9 | Standard Deviation 6.15 | score on a scale |
| Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) | Placebo | Change from Baseline to Week 12 | -9.3 | Standard Deviation 10.21 | score on a scale |
| Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) | Relamorelin 10 μg | Change from Baseline to Week 12 | -10.2 | Standard Deviation 9.24 | score on a scale |
| Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | Placebo | 19.1 | percentage of participants | ||
| Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | Relamorelin 10 μg | 18.7 | percentage of participants | ||
| Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | Placebo | 32.9 | percentage of participants | ||
| Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | Relamorelin 10 μg | 38.1 | percentage of participants | ||
| Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | Placebo | 27.0 | percentage of participants | ||
| Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | Relamorelin 10 μg | 36.1 | percentage of participants | ||
| Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | Placebo | 27.0 | percentage of participants | ||
| Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | Relamorelin 10 μg | 31.6 | percentage of participants | ||
| Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | Placebo | 23.7 | percentage of participants | ||
| Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the 12-week Treatment Period | Relamorelin 10 μg | 27.7 | percentage of participants | ||
| Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE) | Placebo | 75 | Participants | ||
| Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE) | Relamorelin 10 μg | 86 | Participants | ||
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Placebo | Eosinophils Absolute Cell Count [10^9/liter (L)]: >3×Upper Limit of Normal Value (ULN) | 0 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Relamorelin 10 μg | Eosinophils Absolute Cell Count [10^9/liter (L)]: >3×Upper Limit of Normal Value (ULN) | 1 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Placebo | Hematocrit (RATIO): >1.1×ULN | 1 | Participants | |
| Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results | Relamorelin 10 μg | Hematocrit (RATIO): >1.1×ULN | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03426345/results